序号 |
标题 |
次数 |
作者 |
发布时间 |
79786 |
基因点突变细胞株技术流程-CRISPR/Cas9技术 |
166 |
axc |
2024-12-12 |
79787 |
定点突变的目的及原理 |
296 |
axc |
2024-12-12 |
79788 |
基因定点突变技术 |
193 |
axc |
2024-12-12 |
79789 |
DOTA-JR-11,1039726-31-2,白色粉末状螯合剂 |
160 |
h |
2024-12-11 |
79790 |
DOTA-(Tyr3)-octreotate,204318-14-9,类似奥曲肽的多肽 |
128 |
h |
2024-12-11 |
79791 |
Edotreotide(DOTATOC),生长抑素类似物 |
151 |
h |
2024-12-11 |
79792 |
p-SCN-Bn-DOTA,127985-74-4,可用于标记多肽 |
142 |
h |
2024-12-11 |
79793 |
PAMAM-PEG-DOTA-Gd,聚酰胺-胺聚乙二醇DOTA钆 |
105 |
h |
2024-12-11 |
79794 |
螯合剂多肽,cyclo(RGDFK(DOTA)) |
140 |
h |
2024-12-11 |
79795 |
质粒构建的原理及方法 |
619 |
axc |
2024-12-11 |
79796 |
什么是基因过表达(gene overexpression) |
1211 |
axc |
2024-12-11 |
79797 |
m-PEG6-(CH2)6-phosphonic acid,cas:2028284-71-9 |
119 |
zcy |
2024-12-11 |
79798 |
1201415-84-0,1180007-00-4,DOTA-Lys-Cys-COOH |
97 |
h |
2024-12-11 |
79799 |
CRISPR/Cas9系统基因敲除个别外显子(操作步骤) |
527 |
axc |
2024-12-11 |
79800 |
大环螯合物DOTA,DOTA-RGD |
90 |
h |
2024-12-11 |
79801 |
BocNH-O-(CH₂)₅-COOH BOC 保护基-氨基-五碳链-羧酸 |
158 |
zcy |
2024-12-11 |
79802 |
基因敲除方法,基因敲除小鼠定制服务 |
197 |
axc |
2024-12-11 |
79803 |
"Maleimide-(CH2)5-COONHS cas:55750-63-5 6-(马来酰亚胺基)己酸琥珀酰亚胺酯" |
120 |
zcy |
2024-12-11 |
79804 |
质粒构建的原理、步骤|质粒构建定制服务 |
469 |
axc |
2024-12-11 |
79805 |
DOTA-「Tyr3」-Octreotide,Edotreotide,奥曲肽的多肽 |
143 |
h |
2024-12-11 |
79806 |
Mal-PEG-CH2CO2H(马来酰亚胺) |
120 |
WYQ |
2024-12-11 |
79807 |
Stearic acid-PEG-CH2CO2H |
139 |
WYQ |
2024-12-11 |
79808 |
Dotatate,DOTA-奥曲肽 |
143 |
h |
2024-12-11 |
79809 |
螯合剂多肽DOTA-cyclo(RGDfK) |
118 |
h |
2024-12-11 |
79810 |
Biotin-PEG-CH2CO2H(生物素)(聚乙二醇)(甲基羧酸) |
163 |
WYQ |
2024-12-11 |
79811 |
Pomalidomide-PEG4-CH2COOH (CAS: 2097938-44-6) |
100 |
WYQ |
2024-12-11 |
79812 |
Pomalidomide-PEG2-CH2COOH (CAS: 2143097-05-4) |
107 |
WYQ |
2024-12-11 |
79813 |
Hydroxy-PEG1-CH2-Boc |
119 |
kx |
2024-12-11 |
79814 |
Thalidomide-O-PEG2-CH2-Ald (CAS: 2286368-58-7) |
156 |
WYQ |
2024-12-11 |
79815 |
双功能螯合剂DOTA-多肽;DOTA-cRGD 大环螯合剂修饰靶向环肽 |
117 |
h |
2024-12-11 |
79816 |
DSPE-PEG-CH2COOH(CAS: 474922-20-8) |
147 |
WYQ |
2024-12-11 |
79817 |
质粒构建的过程,制备方法 |
337 |
axc |
2024-12-11 |
79818 |
Tos-PEG1-CH2-Boc的应用和用途 |
159 |
kx |
2024-12-11 |
79819 |
204318-14-9,DOTA-(Tyr3)-octreotate,依多曲肽 |
83 |
h |
2024-12-11 |
79820 |
"Maleimide-(CH2)2-COOH cas:7423-55-4 3-马来酰亚胺基丙酸" |
187 |
zcy |
2024-12-11 |
79821 |
Propargyl-PEG3-CH2CO2H |
147 |
WYQ |
2024-12-11 |
79822 |
DOTA多肽分子探针,619300-53-7 |
127 |
h |
2024-12-11 |
79823 |
t-Boc-Aminooxy-PEG2-CH2CO2tBu(CAS: 2100306-57-6) |
98 |
WYQ |
2024-12-11 |
79824 |
β-NF-CH2-OH |
139 |
kx |
2024-12-11 |
79825 |
PEG5-(CH2CO2t-Butyl)2(CAS: 211746-78-0) |
141 |
WYQ |
2024-12-11 |
79826 |
Hydroxy-PEG4-CH2-Boc |
165 |
kx |
2024-12-11 |
79827 |
PEG6-(CH2CO2t-Butyl)2(CAS: 211746-79-1) |
136 |
WYQ |
2024-12-11 |
79828 |
七肽DOTA-YLYEIAR,1262403-91-7 |
121 |
h |
2024-12-11 |
79829 |
质粒构建的原理与类型 |
174 |
axc |
2024-12-11 |
79830 |
Thalidomide-5-NH2-CH2-COOH |
143 |
kx |
2024-12-11 |